SGMO vs. BLUE, CLLS, ATRA, ADAP, LXRX, VNDA, XOMA, AGEN, EBS, and CDXS
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include bluebird bio (BLUE), Cellectis (CLLS), Atara Biotherapeutics (ATRA), Adaptimmune Therapeutics (ADAP), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Agenus (AGEN), Emergent BioSolutions (EBS), and Codexis (CDXS). These companies are all part of the "medical" sector.
Sangamo Therapeutics (NASDAQ:SGMO) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, community ranking, institutional ownership, media sentiment and risk.
Sangamo Therapeutics currently has a consensus price target of $5.67, suggesting a potential upside of 782.38%. bluebird bio has a consensus price target of $5.74, suggesting a potential upside of 495.90%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Sangamo Therapeutics is more favorable than bluebird bio.
In the previous week, bluebird bio had 7 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 10 mentions for bluebird bio and 3 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 1.89 beat bluebird bio's score of 0.47 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
bluebird bio has a net margin of -419.64% compared to Sangamo Therapeutics' net margin of -1,749.06%. bluebird bio's return on equity of -34.32% beat Sangamo Therapeutics' return on equity.
56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 87.4% of bluebird bio shares are owned by institutional investors. 2.8% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 2.1% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Sangamo Therapeutics has higher revenue and earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
bluebird bio received 596 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 71.78% of users gave bluebird bio an outperform vote while only 62.71% of users gave Sangamo Therapeutics an outperform vote.
Sangamo Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.
Summary
bluebird bio beats Sangamo Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
